Aquyre Biosciences Announces Appointment of F. Samuel Eberts III as CEO and Chairman of the Board of Directors & Founder Bertrand de Poly as Chief Strategy & Technology Officer
Aquyre Biosciences, Inc. today announced the appointment of F. Samuel Eberts III as Chief Executive Officer and Chairman of its Board of Directors. Founder Bertrand de Poly will assume the role of Chief Strategy & Technology Officer, focusing on strategy and technological development, along with his continued service on the board.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230503005760/en/
F. Samuel Eberts III, Chief Executive Officer and Chairman of the Board of Directors (Photo: Business Wire)
This evolution in management aims to take the company to its next stage of growth, building on recent achievements including the acceptance of a clinical study manuscript with Johnson & Johnson at Boston University and Fox Chase Cancer Center, to be presented at the American Thoracic Society meeting in Washington, DC on May 19-24, 2023.
Samuel Eberts brings to Aquyre Biosciences decades of experience at the intersection of healthcare, law, and academia. His varied career includes equity partnership and board, and investment committee membership at a private equity firm whose collaboration with Harvard-affiliated Mass General’s Wellman Center facilitated world-class medical insights, and ongoing engagements as a Partner at Market Street HealthCare Partners, a private equity sponsor for healthcare investments. For 15 years, Sam was part of the senior management team at LabCorp, where he served as Chief Legal Officer, Corporate Secretary, and Senior Vice President of Corporate Affairs, with oversight of regulatory, government relations, and merger and acquisition activities. He is a senior advisor for healthcare investments to Aquyre’s shareholder, Invescore. Sam is also a Senior Lecturing Fellow at Duke University School of Law, a member of the advisory board for the Wilson Center, and has served on the World Policy Institute Advisory Board, the Harvard Law School Corporate Governance Forum, and the John F. Kennedy School of Government Healthcare Policy Leadership Council. He also serves on the board of several non-profit organizations.
“I am delighted that Samuel has agreed to help take Aquyre to the next level of its growth journey as we further refine our technology and scale our partner solutions and corporate operations. I look forward to working with him to help ensure the success of our company,” said Bertrand de Poly.
“I am particularly pleased that among the many shareholders of Aquyre, Canon Medical Systems Corporation, the medical equipment subsidiary of the optical, imaging, and industrial multinational Canon, Inc., is a strategic investor,” said Samuel Eberts. “I am honored to be leading such an impressive collection of people and products and am excited about the potential of Aquyre Biosciences. It is humbling and exciting to be part of an organization that will play an important role in healthcare. We are well positioned to bring a new level of precision in diagnosis of cancer, improving the lives of patients.”
About Aquyre Biosciences
Aquyre Biosciences, Inc is the creator of CelTivity™, the industry leader in two-minute lung biopsy adequacy assessment. Powered by two proprietary technologies including Dynamic Cell Imaging™ (DCI), CelTivity can scan a biopsy and measure intracellular and metabolic activity throughout extracted tissue. This activity is presented in a heatmap, making it easy to interpret. The assessment does not require any cutting or staining, meaning the same tissue assessed for adequacy can go to final pathology to review for cancer, granuloma, lymphocytes, and more. Aquyre Biosciences is headquartered out of Weston, Mass. For more information, please visit www.aquyre.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230503005760/en/
Contact information
Emily Ritacco
Director of Marketing
eritacco@aquyre.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Tecnotree Mentioned in Various 2025 Gartner® Research8.12.2025 10:41:00 EET | Press release
Tecnotree is a 5G-ready digital Business Support System (BSS) provider with advanced AI/ML capabilities and multi-cloud extensibility. The company has been listed across thirteen 2025 Gartner research spanning Digital BSS, AI-driven monetization, digital marketplace enablement, and customer experience transformation. We believe these mentions reflects the continued relevance and strong applicability of Tecnotree’s solutions within the technology domains evaluated by Gartner. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251208688494/en/ Tecnotree Mentioned in Various 2025 Gartner® Research The research span Market Guides, Hype Cycles, Magic Quadrants, Critical Capabilities, and Competitive Landscape reports, which we think collectively provides an overview of how various technologies are evolving across the communications ecosystem. We believe that Tecnotree’s appearance across these research categories underscores what we
ATEC2025·Real-World Extreme Challenge Concludes with Zhejiang University Team Claiming $150,000 Prize for Breakthrough in Fully Autonomous Robotics8.12.2025 10:25:00 EET | Press release
The ATEC2025·Real-World Extreme Challenge successfully concluded on December 7 on the campus of The Chinese University of Hong Kong. A team from Zhejiang University emerged victorious from a field of 13 talented international squads by demonstrating exceptional fully autonomous embodied intelligence, securing the top prize of $150,000 USD. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207877880/en/ A Zhejiang University team wins ATEC2025·Real-World Extreme Challenge Organized by the Chinese University of Hong Kong and co-hosted by Advanced Technology Exploration Community (ATEC), Peking University, Beijing Normal University, and Ant Group, ATEC2025·Real-World Extreme Challenge was the world’s first intelligent robotics challenge held entirely outdoors on natural terrain—featuring rugged hills, stone steps, swaying bridges, and uneven slopes—to rigorously test robots’ ability to operate without human intervention. Under
AI Won't Transform Mobility Without Unprecedented Collaboration, Study Reveals8.12.2025 10:25:00 EET | Press release
Artificial intelligence is quietly reshaping global transportation systems, but most deployments remain isolated pilots that haven't achieved scale – and the gap between AI's promise and its execution is widening, according to a landmark study launched today at CoMotion GLOBAL in Riyadh. The Envisioning the Future of Mobility Powered by AI report, developed by the MIT Mobility Initiative and Kearney Advanced Mobility Institute, analyzed input from 55 leading global organizations, including Google, Lyft, Uber Freight, Deutsche Bahn, and NEOM. The study mapped real-world AI applications across mobility systems in Europe, the Americas, APAC, and the Middle East – revealing both breakthrough potential and fundamental challenges in bringing AI-powered mobility to scale. The report identifies a critical dynamic reshaping the industry: AI doesn't simply replicate human intelligence – it excels dramatically in some functions while failing unpredictably in others. This "jagged frontier" creates
SIAL Paris 2026 : The Entire Food Industry in One Place – An Unmissable Event for Professionals8.12.2025 10:00:00 EET | Press release
With less than a year to go, SIAL Parisonce again stands as a key international gathering for food industry professionals. With 85% of exhibition space already booked, the show demonstrates very strong momentum and appeal. SIAL Paris will welcome 295,000 professionals from 200 countries across a stunning 280,000 m² of exhibition space, covering all sectors of the food industry. Innovation at the core of global food transformation In a context marked by major demographic, environmental and geopolitical challenges, SIAL Paris stands as THE hub where innovation drives action, business, and transformation. It brings across all sectors’ ideas, projects, and solutions that address today’s challenges, all while inspiring food business around the world. As in every edition, the show will offer a unique immersive experience, facilitating meaningful meetings and business opportunities. SIAL Paris serves as the global international showcase for food innovation, allowing brands and companies to ex
Merz Therapeutics to Present Broad Range of Clinical, Real-World and Mechanistic Data at TOXINS 20268.12.2025 09:00:00 EET | Press release
Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced that the company will present more than 20 clinical and non-clinical abstracts and posters spanning spasticity, movement disorders, and neurotoxin science at the TOXINS 2026 8th International Conference, taking place January 14–17, 2026, in Madrid, Spain. These presentations underscore the company’s commitment to addressing unmet needs in neurological disorders. “Our research reflects a relentless focus on improving patient outcomes through innovation in neurotoxin science,” said Dr. Stefan Albrecht, Chief Scientific and Medical Officer at Merz Therapeutics. “By presenting these new data at TOXINS 2026, we aim to foster scientific exchange and advance treatment strategies that address real-world challenges for patients and clinicians.” Merz Therapeutics will share new findings reflecting its continued dedication to advancing neurotoxin science. These include: Lower Limb Spasticity Incobotulinumto
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom